跳至主要内容
临床试验/NCT05163951
NCT05163951招募中不适用

Effectiveness and Safety of Trabeculectomy and Peripheral Iridectomy Plus Goniotomy in Advanced Primary Angle-closure Glaucoma: a Multicenter Non-inferiority Randomized Controlled Trial

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2022年1月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
88
试验地点
1
主要终点
Intraocular pressure at postoperative 12 months

研究概览

简要总结

A multicenter, parallel, open, non-inferior randomized controlled trial is conducted to compare the effectiveness and safety of trabeculectomy and peripheral iridectomy plus goniotomy (TVG) in the treatment of advanced primary angle closure glaucoma with no or mild cataracts.

详细描述

Primary angle-closure glaucoma (PACG) has a high prevalence and blinding rate in China. The routine first-line treatment of advanced PACG is trabeculectomy, especially in those without cataract. However, due to surgery complications and exhausting post-surgery caring, traditional trabeculectomy is not an ideal choice in clinical practice, particularly in patients with high risk of complications such as younger age and shorter axial length. Peripheral iridectomy (SPI) plus intraocular pressure (IOP)-lowering medications is an alternative.

Minimally invasive glaucoma surgery (MIGS) has recently showed its safety and effectiveness in the treatment of PACG, usually combined with cataract surgery, goniosynechialysis (GSL) and goniotomy(GT). The safety and effectiveness of phacoemulsification and intraocular lens implantation (PEI)+GSL+GT in advanced PACG with cataract has been conducted (clinical trials.gov, NCT04878458). It is valuable to explore the safety and efficacy of SPI+GSL+GT in these PACG patients with no or mild cataracts.

Therefore, this study intends to conduct a multicenter, non-inferior randomized controlled clinical trial to compare the effectiveness and safety of trabeculectomy versus SPI+GSL+GT in advanced PACG with no or mild cataracts.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 45-80 years.
  • Eyes diagnosed with advanced PACG who meet following criteria a, b, and c; or a, b, and d:
  • PAS: ≥180° range, including nasal and inferior quadrants;
  • IOP >21 mmHg with or without anti-glaucoma medications (the medications include the maximally tolerated medications), taken with the Goldmann applanation tonometer;
  • Glaucomatous optic neuropathy (cup-to-disc [C/D] ratio ≥0.7, C/D asymmetry >0.2, or rim width at the superior and inferior temporal areas <0.1 of the vertical diameters of the optic disc);
  • Glaucomatous visual field defects (nasal step, arcuate scotoma, and paracentral scotoma on a reliable Humphrey analyzer and a mean deviation of ≤-12 dB).
  • No or mild cataracts and uncorrected visual acuity of ≥0.63 (Early Treatment Diabetic Retinopathy Study chart);
  • Axial length of ≥20 mm.

排除标准

  • History of ocular surgery or trauma.
  • Retinal disease that influences the collection of ocular parameters or other types of glaucoma, including open-angle glaucoma, secondary angle-closure glaucoma, steroidal glaucoma, angle recession glaucoma, neovascular glaucoma, nanophthalmos, and pseudoexfoliation syndrome.
  • Monophthalmia (best-corrected visual acuity of <0.01 in the non-study eye).
  • An International Standardized Ratio of >3.0, for patients receiving warfarin or anticoagulant therapy before surgery.
  • Patients with serious systemic diseases.
  • Pregnant or lactating women.
  • If both eyes are eligible for the study, the eye with the worse visual field or optic nerve will be included.

结局指标

主要结局

Intraocular pressure at postoperative 12 months

时间窗: Postoperative 12 month

Intraocular pressure after surgery using Goldmann or non-contact tonometer.

次要结局

  • Cumulative success rate of surgery(Postoperative 12, 24, 36 months)
  • The numbers of anti-glaucoma medications(Postoperative 0, 1, 7 days, and 1, 3, 6, 12, 18, 24, 30, 36 months)
  • Intraoperative and postoperative complications(Postoperative 0, 1, 7 days, and 1, 3, 6, 12, 18, 24, 30, 36 months)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiulan Zhang

Director of Clinical Research Center

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验

Trabeculectomy Versus Peripheral Iridectomy Plus... | 临床试验